Year |
Citation |
Score |
2022 |
Candito DA, Simov V, Gulati A, Kattar S, Chau RW, Lapointe BT, Methot JL, DeMong DE, Graham TH, Kurukulasuriya R, Keylor MH, Tong L, Morriello GJ, Acton JJ, Pio B, ... ... Scott JD, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. Journal of Medicinal Chemistry. PMID 36475697 DOI: 10.1021/acs.jmedchem.2c01605 |
0.645 |
|
2021 |
Gulati A, Yeung CS, Lapointe B, Kattar SD, Gunaydin H, Scott JD, Childers KK, Methot JL, Simov V, Kurukulasuriya R, Pio B, Morriello GJ, Liu P, Tang H, Neelamkavil S, et al. Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. Rsc Medicinal Chemistry. 12: 1164-1173. PMID 34355182 DOI: 10.1039/d1md00097g |
0.374 |
|
2017 |
Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, et al. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Journal of Medicinal Chemistry. PMID 28245354 DOI: 10.1021/Acs.Jmedchem.7B00045 |
0.646 |
|
2015 |
Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, et al. MLi-2, a potent, selective and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. The Journal of Pharmacology and Experimental Therapeutics. PMID 26407721 DOI: 10.1124/Jpet.115.227587 |
0.648 |
|
2015 |
Nygren PJ, Scott JD. Therapeutic strategies for anchored kinases and phosphatases: exploiting short linear motifs and intrinsic disorder. Frontiers in Pharmacology. 6: 158. PMID 26283967 DOI: 10.3389/fphar.2015.00158 |
0.316 |
|
2015 |
Samelson BK, Gore BB, Whiting JL, Nygren PJ, Purkey AM, Colledge M, Langeberg LK, Dell'Acqua ML, Zweifel LS, Scott JD. A-kinase Anchoring Protein 79/150 Recruits Protein Kinase C to Phosphorylate Roundabout Receptors. The Journal of Biological Chemistry. 290: 14107-19. PMID 25882844 DOI: 10.1074/Jbc.M115.637470 |
0.303 |
|
2002 |
Scott JD, Williams RM. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chemical Reviews. 102: 1669-730. PMID 11996547 DOI: 10.1021/Cr010212U |
0.317 |
|
2002 |
Scott JD, Williams RM. Total synthesis of (-)-tetrazomine. Determination of the stereochemistry of tetrazomine and the synthesis and biological activity of tetrazomine analogues. Journal of the American Chemical Society. 124: 2951-6. PMID 11902886 DOI: 10.1021/Ja0174027 |
0.476 |
|
2001 |
Scott JD, Williams RM. Total Synthesis of (-)-Tetrazomine and Determination of Its Stereochemistry. Angewandte Chemie (International Ed. in English). 40: 1463-1465. PMID 29712345 DOI: 10.1002/1521-3773(20010417)40:8<1463::Aid-Anie1463>3.0.Co;2-8 |
0.443 |
|
2001 |
Scott JD, Williams RM. Total Synthesis of (-)-Tetrazomine and Determination of Its Stereochemistry This work was supported by the National Institutes of Health (Grant CA85419). We are grateful to Yamanouchi Pharmaceutical Co. for providing a generous gift of natural tetrazomine. Angewandte Chemie (International Ed. in English). 40: 1463-1465. PMID 11317303 DOI: 10.1002/1521-3773(20010417)40:8<1463::AID-ANIE1463>3.0.CO;2-8 |
0.335 |
|
2000 |
Herberich B, Scott JD, Williams RM. Synthesis of a netropsin conjugate of a water-soluble epi-quinocarcin analogue: the importance of stereochemistry at nitrogen. Bioorganic & Medicinal Chemistry. 8: 523-32. PMID 10732968 DOI: 10.1016/S0968-0896(99)00314-4 |
0.429 |
|
2000 |
Scott JD, Williams RM. Synthetic studies on tetrazomine: lipase PS resolution of racemic cis-β-hydroxypipecolic acid Tetrahedron Letters. 41: 8413-8416. DOI: 10.1016/S0040-4039(00)01527-6 |
0.418 |
|
1998 |
Scott JD, Tippie TN, Williams RM. Synthetic studies on tetrazomine: Stereochemical assignment of the β-hydroxypipecolic acid Tetrahedron Letters. 39: 3659-3662. DOI: 10.1016/S0040-4039(98)00642-X |
0.418 |
|
Show low-probability matches. |